{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:27:18Z","timestamp":1791358038883,"version":"4.3.1"},"publisher-location":"Singapore","reference-count":68,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811581038","type":"print"},{"value":"9789811581045","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-981-15-8104-5_6","type":"book-chapter","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T04:33:38Z","timestamp":1604637218000},"page":"73-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas"],"prefix":"10.1007","author":[{"given":"Victor M.","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,7]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. \nhttps:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11060-016-2363-y","volume":"132","author":"SEV van Zanten","year":"2017","unstructured":"van Zanten SEV et al (2017) Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. J Neuro Oncol 132:255\u2013266. \nhttps:\/\/doi.org\/10.1007\/s11060-016-2363-y","journal-title":"J Neuro Oncol"},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semradonc.2009.09.005","volume":"20","author":"TE Merchant","year":"2010","unstructured":"Merchant TE, Pollack IF, Loeffler JS (2010) Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol 20:58\u201366. \nhttps:\/\/doi.org\/10.1016\/j.semradonc.2009.09.005","journal-title":"Semin Radiat Oncol"},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/cam4.410","volume":"4","author":"PM de Blank","year":"2015","unstructured":"de Blank PM et al (2015) Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. Cancer Med 4:608\u2013619. \nhttps:\/\/doi.org\/10.1002\/cam4.410","journal-title":"Cancer Med"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","volume":"44","author":"G Wu","year":"2012","unstructured":"Wu G et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251\u2013253. \nhttps:\/\/doi.org\/10.1038\/ng.1102","journal-title":"Nat Genet"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","volume":"130","author":"D Castel","year":"2015","unstructured":"Castel D et al (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130:815\u2013827. \nhttps:\/\/doi.org\/10.1007\/s00401-015-1478-0","journal-title":"Acta Neuropathol"},{"key":"6_CR7","doi-asserted-by":"publisher","unstructured":"Lu VM, Alvi MA, McDonald KL, Daniels DJ (2018) Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis. J Neurosurg Pediatr:1\u20139. \nhttps:\/\/doi.org\/10.3171\/2018.9.Peds18419","DOI":"10.3171\/2018.9.Peds18419"},{"key":"6_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40478-018-0614-1","volume":"6","author":"D Castel","year":"2018","unstructured":"Castel D et al (2018) Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant\u2019 discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. Acta Neuropathol Commun 6:117. \nhttps:\/\/doi.org\/10.1186\/s40478-018-0614-1","journal-title":"Acta Neuropathol Commun"},{"key":"6_CR9","doi-asserted-by":"publisher","unstructured":"Fang D et al (2018) H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers. eLife 7. \nhttps:\/\/doi.org\/10.7554\/eLife.36696","DOI":"10.7554\/eLife.36696"},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2015.00237","volume":"5","author":"MI Vanan","year":"2015","unstructured":"Vanan MI, Eisenstat DD (2015) DIPG in children \u2013 what can we learn from the past? Front Oncol 5:237. \nhttps:\/\/doi.org\/10.3389\/fonc.2015.00237","journal-title":"Front Oncol"},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1126\/science.1253799","volume":"346","author":"K Funato","year":"2014","unstructured":"Funato K, Major T, Lewis PW, Allis CD, Tabar V (2014) Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 346:1529\u20131533. \nhttps:\/\/doi.org\/10.1126\/science.1253799","journal-title":"Science"},{"key":"6_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature09652","volume":"469","author":"LS Churchman","year":"2011","unstructured":"Churchman LS, Weissman JS (2011) Nascent transcript sequencing visualizes transcription at nucleotide resolution. Nature 469:368\u2013373. \nhttps:\/\/doi.org\/10.1038\/nature09652","journal-title":"Nature"},{"key":"6_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1126\/science.1172926","volume":"325","author":"C Hodges","year":"2009","unstructured":"Hodges C, Bintu L, Lubkowska L, Kashlev M, Bustamante C (2009) Nucleosomal fluctuations govern the transcription dynamics of RNA polymerase II. Science 325:626\u2013628. \nhttps:\/\/doi.org\/10.1126\/science.1172926","journal-title":"Science"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1126\/science.1246755","volume":"342","author":"TS Furey","year":"2013","unstructured":"Furey TS, Sethupathy P (2013) Genetics. Genetics driving epigenetics. Science 342:705\u2013706. \nhttps:\/\/doi.org\/10.1126\/science.1246755","journal-title":"Science"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1101\/gad.217778.113","volume":"27","author":"K-M Chan","year":"2013","unstructured":"Chan K-M et al (2013) The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27:985\u2013990. \nhttps:\/\/doi.org\/10.1101\/gad.217778.113","journal-title":"Genes Dev"},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00401-014-1319-6","volume":"128","author":"P Buczkowicz","year":"2014","unstructured":"Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C (2014) Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol 128:573\u2013581. \nhttps:\/\/doi.org\/10.1007\/s00401-014-1319-6","journal-title":"Acta Neuropathol"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11060-014-1675-z","volume":"121","author":"P Pathak","year":"2015","unstructured":"Pathak P et al (2015) Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM. J Neuro-Oncol 121:489\u2013497. \nhttps:\/\/doi.org\/10.1007\/s11060-014-1675-z","journal-title":"J Neuro-Oncol"},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2176\/nmc.ra.2017-0018","volume":"57","author":"R Hashizume","year":"2017","unstructured":"Hashizume R (2017) Epigenetic targeted therapy for diffuse intrinsic pontine glioma. Neurol Med Chir 57:331\u2013342. \nhttps:\/\/doi.org\/10.2176\/nmc.ra.2017-0018","journal-title":"Neurol Med Chir"},{"key":"6_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrm1960","volume":"7","author":"BT Seet","year":"2006","unstructured":"Seet BT, Dikic I, Zhou MM, Pawson T (2006) Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 7:473\u2013483. \nhttps:\/\/doi.org\/10.1038\/nrm1960","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/15592294.2016.1278095","volume":"12","author":"E Maury","year":"2017","unstructured":"Maury E, Hashizume R (2017) Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: insight into epigenetic therapies. Epigenetics 12:353\u2013369. \nhttps:\/\/doi.org\/10.1080\/15592294.2016.1278095","journal-title":"Epigenetics"},{"key":"6_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00401-019-01975-4","volume":"137","author":"AB Silveira","year":"2019","unstructured":"Silveira AB et al (2019) H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathol 137:637\u2013655. \nhttps:\/\/doi.org\/10.1007\/s00401-019-01975-4","journal-title":"Acta Neuropathol"},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/bpa.12042","volume":"23","author":"S Venneti","year":"2013","unstructured":"Venneti S et al (2013) Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol 23:558\u2013564. \nhttps:\/\/doi.org\/10.1111\/bpa.12042","journal-title":"Brain Pathol"},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nm.4296","volume":"23","author":"A Piunti","year":"2017","unstructured":"Piunti A et al (2017) Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med 23:493\u2013500. \nhttps:\/\/doi.org\/10.1038\/nm.4296","journal-title":"Nat Med"},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"R Cao","year":"2002","unstructured":"Cao R et al (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:1039\u20131043. \nhttps:\/\/doi.org\/10.1126\/science.1076997","journal-title":"Science"},{"key":"6_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ceb.2004.03.010","volume":"16","author":"AH Lund","year":"2004","unstructured":"Lund AH, van Lohuizen M (2004) Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16:239\u2013246. \nhttps:\/\/doi.org\/10.1016\/j.ceb.2004.03.010","journal-title":"Curr Opin Cell Biol"},{"key":"6_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nature06145","volume":"449","author":"K Agger","year":"2007","unstructured":"Agger K et al (2007) UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449:731\u2013734. \nhttps:\/\/doi.org\/10.1038\/nature06145","journal-title":"Nature"},{"key":"6_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature11262","volume":"488","author":"L Kruidenier","year":"2012","unstructured":"Kruidenier L et al (2012) A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488:404\u2013408. \nhttps:\/\/doi.org\/10.1038\/nature11262","journal-title":"Nature"},{"key":"6_CR28","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.3716","volume":"20","author":"R Hashizume","year":"2014","unstructured":"Hashizume R et al (2014) Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 20:1394\u20131396. \nhttps:\/\/doi.org\/10.1038\/nm.3716","journal-title":"Nat Med"},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature13605","volume":"514","author":"P Ntziachristos","year":"2014","unstructured":"Ntziachristos P et al (2014) Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514:513\u2013517. \nhttps:\/\/doi.org\/10.1038\/nature13605","journal-title":"Nature"},{"key":"6_CR30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","volume":"24","author":"S Bender","year":"2013","unstructured":"Bender S et al (2013) Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24:660\u2013672. \nhttps:\/\/doi.org\/10.1016\/j.ccr.2013.10.006","journal-title":"Cancer Cell"},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nm.4293","volume":"23","author":"F Mohammad","year":"2017","unstructured":"Mohammad F et al (2017) EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 23:483\u2013492. \nhttps:\/\/doi.org\/10.1038\/nm.4293","journal-title":"Nat Med"},{"key":"6_CR32","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/1541-7786.Mcr-16-0389","volume":"15","author":"FJ Cordero","year":"2017","unstructured":"Cordero FJ et al (2017) Histone H3.3K27M represses p16 to accelerate Gliomagenesis in a murine model of DIPG. Mol Cancer Res 15:1243\u20131254. \nhttps:\/\/doi.org\/10.1158\/1541-7786.Mcr-16-0389","journal-title":"Mol Cancer Res"},{"key":"6_CR33","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"SK Knutson","year":"2014","unstructured":"Knutson SK et al (2014) Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 13:842. \nhttps:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0773","journal-title":"Mol Cancer Ther"},{"key":"6_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1021\/ml3003346","volume":"3","author":"SK Verma","year":"2012","unstructured":"Verma SK et al (2012) Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett 3:1091\u20131096. \nhttps:\/\/doi.org\/10.1021\/ml3003346","journal-title":"ACS Med Chem Lett"},{"key":"6_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0042-105292","volume":"228","author":"M Wiese","year":"2016","unstructured":"Wiese M et al (2016) No significant cytotoxic effect of the EZH2 inhibitor Tazemetostat (EPZ-6438) on pediatric glioma cells with wildtype histone 3 or mutated histone 3.3. Klinische Padiatr 228:113\u2013117. \nhttps:\/\/doi.org\/10.1055\/s-0042-105292","journal-title":"Klinische Padiatr"},{"key":"6_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/jco.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann IM et al (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268\u2013273. \nhttps:\/\/doi.org\/10.1200\/jco.2005.01.5180","journal-title":"J Clin Oncol"},{"key":"6_CR37","doi-asserted-by":"publisher","first-page":"9211","DOI":"10.1158\/0008-5472.Can-09-1622","volume":"69","author":"ML Suva","year":"2009","unstructured":"Suva ML et al (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69:9211\u20139218. \nhttps:\/\/doi.org\/10.1158\/0008-5472.Can-09-1622","journal-title":"Cancer Res"},{"key":"6_CR38","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/ijc.27455","volume":"131","author":"I Alimova","year":"2012","unstructured":"Alimova I et al (2012) Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer 131:1800\u20131809. \nhttps:\/\/doi.org\/10.1002\/ijc.27455","journal-title":"Int J Cancer"},{"key":"6_CR39","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ccell.2019.04.004","volume":"35","author":"B Krug","year":"2019","unstructured":"Krug B et al (2019) Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas. Cancer Cell 35:782\u2013797.e788. \nhttps:\/\/doi.org\/10.1016\/j.ccell.2019.04.004","journal-title":"Cancer Cell"},{"key":"6_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2013.03.004","volume":"153","author":"WG Kaelin Jr","year":"2013","unstructured":"Kaelin WG Jr, McKnight SL (2013) Influence of metabolism on epigenetics and disease. Cell 153:56\u201369. \nhttps:\/\/doi.org\/10.1016\/j.cell.2013.03.004","journal-title":"Cell"},{"key":"6_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrd4286","volume":"13","author":"P Filippakopoulos","year":"2014","unstructured":"Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13:337\u2013356. \nhttps:\/\/doi.org\/10.1038\/nrd4286","journal-title":"Nat Rev Drug Discov"},{"key":"6_CR42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1126\/science.1232245","volume":"340","author":"PW Lewis","year":"2013","unstructured":"Lewis PW et al (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340:857\u2013861. \nhttps:\/\/doi.org\/10.1126\/science.1232245","journal-title":"Science"},{"key":"6_CR43","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1126\/science.1255104","volume":"345","author":"H-M Herz","year":"2014","unstructured":"Herz H-M et al (2014) Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling. Science 345:1065. \nhttps:\/\/doi.org\/10.1126\/science.1255104","journal-title":"Science"},{"key":"6_CR44","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso CS et al (2015) Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21:555\u2013559. \nhttps:\/\/doi.org\/10.1038\/nm.3855","journal-title":"Nat Med"},{"key":"6_CR45","doi-asserted-by":"publisher","first-page":"13498","DOI":"10.1021\/ja5060934","volume":"136","author":"ZZ Brown","year":"2014","unstructured":"Brown ZZ et al (2014) Strategy for \"detoxification\" of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2. J Am Chem Soc 136:13498\u201313501. \nhttps:\/\/doi.org\/10.1021\/ja5060934","journal-title":"J Am Chem Soc"},{"key":"6_CR46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1574892810666150317144511","volume":"10","author":"C De Souza","year":"2015","unstructured":"De Souza C, Chatterji BP (2015) HDAC inhibitors as novel anti-cancer therapeutics. Recent Pat Anticancer Drug Discov 10:145\u2013162","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"6_CR47","doi-asserted-by":"publisher","unstructured":"Li Y, Seto E (2016) HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 6. \nhttps:\/\/doi.org\/10.1101\/cshperspect.a026831","DOI":"10.1101\/cshperspect.a026831"},{"key":"6_CR48","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/1078-0432.Ccr-07-4262","volume":"14","author":"L Ellis","year":"2008","unstructured":"Ellis L et al (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500\u20134510. \nhttps:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-4262","journal-title":"Clin Cancer Res"},{"key":"6_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169485","volume":"12","author":"T Hennika","year":"2017","unstructured":"Hennika T et al (2017) Pre-clinical study of Panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PLoS One 12:e0169485. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0169485","journal-title":"PLoS One"},{"key":"6_CR50","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/annonc\/mdw044","volume":"27","author":"S Thomas","year":"2016","unstructured":"Thomas S et al (2016) A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol 27:947\u2013952. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdw044","journal-title":"Ann Oncol"},{"key":"6_CR51","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/17474086.2017.1369399","volume":"10","author":"P Richardson","year":"2017","unstructured":"Richardson P et al (2017) Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. Expert Rev Hematol 10:933\u2013939. \nhttps:\/\/doi.org\/10.1080\/17474086.2017.1369399","journal-title":"Expert Rev Hematol"},{"key":"6_CR52","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fonc.2017.00254","volume":"7","author":"FE El-Khouly","year":"2017","unstructured":"El-Khouly FE et al (2017) Effective drug delivery in diffuse intrinsic pontine glioma: a theoretical model to identify potential candidates. Front Oncol 7:254. \nhttps:\/\/doi.org\/10.3389\/fonc.2017.00254","journal-title":"Front Oncol"},{"key":"6_CR53","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1073\/pnas.73.11.3937","volume":"73","author":"K Marushige","year":"1976","unstructured":"Marushige K (1976) Activation of chromatin by acetylation of histone side chains. Proc Natl Acad Sci U S A 73:3937\u20133941. \nhttps:\/\/doi.org\/10.1073\/pnas.73.11.3937","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6_CR54","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.620","volume":"8","author":"E Wadhwa","year":"2016","unstructured":"Wadhwa E, Nicolaides T (2016) Bromodomain inhibitor review: Bromodomain and extra-terminal family protein inhibitors as a potential new therapy in central nervous system tumors. Cureus 8:e620. \nhttps:\/\/doi.org\/10.7759\/cureus.620","journal-title":"Cureus"},{"key":"6_CR55","doi-asserted-by":"publisher","first-page":"a018663","DOI":"10.1101\/cshperspect.a018663","volume":"6","author":"J Qi","year":"2014","unstructured":"Qi J (2014) Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure. Cold Spring Harb Perspect Biol 6:a018663. \nhttps:\/\/doi.org\/10.1101\/cshperspect.a018663","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6_CR56","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13578-017-0184-0","volume":"7","author":"Y Zhang","year":"2017","unstructured":"Zhang Y et al (2017) Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. Cell Biosci 7:56. \nhttps:\/\/doi.org\/10.1186\/s13578-017-0184-0","journal-title":"Cell Biosci"},{"key":"6_CR57","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.molcel.2010.08.020","volume":"39","author":"SS Gehani","year":"2010","unstructured":"Gehani SS et al (2010) Polycomb group protein displacement and gene activation through MSK-dependent H3K27me3S28 phosphorylation. Mol Cell 39:886\u2013900. \nhttps:\/\/doi.org\/10.1016\/j.molcel.2010.08.020","journal-title":"Mol Cell"},{"key":"6_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molcel.2006.12.014","volume":"25","author":"AJ Ruthenburg","year":"2007","unstructured":"Ruthenburg AJ, Allis CD, Wysocka J (2007) Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 25:15\u201330. \nhttps:\/\/doi.org\/10.1016\/j.molcel.2006.12.014","journal-title":"Mol Cell"},{"key":"6_CR59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.molcel.2008.07.002","volume":"31","author":"XJ Yang","year":"2008","unstructured":"Yang XJ, Seto E (2008) Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 31:449\u2013461. \nhttps:\/\/doi.org\/10.1016\/j.molcel.2008.07.002","journal-title":"Mol Cell"},{"key":"6_CR60","doi-asserted-by":"publisher","unstructured":"Schramm K et al (2019) DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for DIPGs. Neuro-Oncology. \nhttps:\/\/doi.org\/10.1093\/neuonc\/noz057","DOI":"10.1093\/neuonc\/noz057"},{"key":"6_CR61","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1128\/MCB.23.17.6129-6138.2003","volume":"23","author":"SJ Nowak","year":"2003","unstructured":"Nowak SJ, Pai C-Y, Corces VG (2003) Protein phosphatase 2A activity affects histone H3 phosphorylation and transcription in Drosophila melanogaster. Mol Cell Biol 23:6129. \nhttps:\/\/doi.org\/10.1128\/MCB.23.17.6129-6138.2003","journal-title":"Mol Cell Biol"},{"key":"6_CR62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1158\/1078-0432.Ccr-14-1592","volume":"21","author":"L Moreno","year":"2015","unstructured":"Moreno L et al (2015) A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res 21:267\u2013273. \nhttps:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1592","journal-title":"Clin Cancer Res"},{"key":"6_CR63","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1073\/pnas.0502413102","volume":"102","author":"SB Hake","year":"2005","unstructured":"Hake SB et al (2005) Serine 31 phosphorylation of histone variant H3.3 is specific to regions bordering centromeres in metaphase chromosomes. Proc Natl Acad Sci U S A 102:6344\u20136349. \nhttps:\/\/doi.org\/10.1073\/pnas.0502413102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6_CR64","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/neuonc\/nox085","volume":"19","author":"JM Figueroa","year":"2017","unstructured":"Figueroa JM et al (2017) Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro-Oncology 19:1494\u20131502. \nhttps:\/\/doi.org\/10.1093\/neuonc\/nox085","journal-title":"Neuro-Oncology"},{"key":"6_CR65","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3892\/br.2015.462","volume":"3","author":"Z Wang","year":"2015","unstructured":"Wang Z et al (2015) MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma. Biomed Rep 3:543\u2013548. \nhttps:\/\/doi.org\/10.3892\/br.2015.462","journal-title":"Biomed Rep"},{"key":"6_CR66","doi-asserted-by":"publisher","unstructured":"Lu VM, Power EA, Zhang L, Daniels DJ (2019) Unlocking the translational potential of circulating nucleosomes for liquid biopsy in diffuse intrinsic pontine glioma. Biomark Med. \nhttps:\/\/doi.org\/10.2217\/bmm-2019-0139","DOI":"10.2217\/bmm-2019-0139"},{"key":"6_CR67","doi-asserted-by":"publisher","first-page":"29654","DOI":"10.3390\/ijms161226180","volume":"16","author":"U Gezer","year":"2015","unstructured":"Gezer U et al (2015) Histone methylation Marks on circulating nucleosomes as novel blood-based biomarker in colorectal cancer. Int J Mol Sci 16:29654\u201329662. \nhttps:\/\/doi.org\/10.3390\/ijms161226180","journal-title":"Int J Mol Sci"},{"key":"6_CR68","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1080\/00365521.2017.1301989","volume":"52","author":"P Syren","year":"2017","unstructured":"Syren P, Andersson R, Bauden M, Ansari D (2017) Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma. Scand J Gastroenterol 52:668\u2013673. \nhttps:\/\/doi.org\/10.1080\/00365521.2017.1301989","journal-title":"Scand J Gastroenterol"}],"container-title":["Advances in Experimental Medicine and Biology","Histone Mutations and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-15-8104-5_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T04:36:34Z","timestamp":1604637394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-15-8104-5_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,7]]},"ISBN":["9789811581038","9789811581045"],"references-count":68,"URL":"https:\/\/doi.org\/10.1007\/978-981-15-8104-5_6","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,7]]},"assertion":[{"value":"7 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}